Stock RPTX REPARE THERAPEUTICS INC.
Add to a list
To use this feature you must be a member
Log inSign up

Highlights Repare Therapeutics Inc.

Equities

RPTX

US7602731025

Real-time Estimate Cboe BZX
Other stock markets
 02:45:44 2024-04-29 pm EDT 		5-day change 1st Jan Change
3.175 USD -0.78% Intraday chart for Repare Therapeutics Inc. -2.76% -56.58%
Apr. 26 Repare Therapeutics Inc. Announces Directorate Changes CI
Feb. 28 Repare Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Highlights

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Repare Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Repare Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Repare Therapeutics Doses First Patient in Phase 1 Clinical Trial of RP-1664
CI
Repare Therapeutics to Collaborate With Debiopharm on Potential Cancer Therapy
MT
Repare Therapeutics Inc. and Debiopharm Partner to Explore the Synthetic Lethal Combination of PKMYT1 and WEE1 Inhibition in Cancer
CI
Repare Therapeutics Unveils Two Programs Expected to Enter Clinical Trials in 2024: Rp-1664, an Oral Plk4 Inhibitor, and Rp-3467, an Oral Pol Inhibitor
CI
Repare Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
Repare Therapeutics Inc. Reports Positive Initial Data from Modules 1 and 2 of its Ongoing Phase 1 Mythic Clinical Trial Evaluating Lunresertib Alone and in Combination with Camonsertib, an ATR Inhibitor
CI
Repare Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
CI
Repare Therapeutics Reports Proof of Concept for Lunresertib (RP-6306) in Clinic, Initial Monotherapy Data from Phase 1 MYTHIC Clinical Trial and Early Insights from Ongoing Combination Trials
CI
Repare Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
CI
Repare Therapeutics Inc. Presents Initial Clinical Data from the Phase 1/2 TRESR and ATTACC Trials Evaluating Camonsertib in Combination with Three PARP Inhibitors at the 2023 AACR Annual Meeting
CI
REPARE THERAPEUTICS INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-K)
AQ
Repare Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2022
CI
REPARE THERAPEUTICS INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)
AQ
Repare Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
CI
REPARE THERAPEUTICS INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)
AQ
Repare Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022
CI
Repare Therapeutics to Get $125 Million Upfront Payment in Camonsertib Deal with Roche -- Stock Jumps 20% After-Hours
MT
Repare Therapeutics Announces a Worldwide License and Collaboration Agreement with Roche for Camonsertib (RP-3500)
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. RPTX Stock
  4. News Repare Therapeutics Inc.
  5. Highlights